Advertisement

Journal of Parasitic Diseases

, Volume 40, Issue 3, pp 935–939 | Cite as

Comparison between intralesional injection of zinc sulfate 2 % solution and intralesional meglumine antimoniate in the treatment of acute old world dry type cutaneous leishmaniasis: a randomized double-blind clinical trial

  • Saeedeh Farajzadeh
  • Maryam Hakimi Parizi
  • Ali Akbar Haghdoost
  • Azadeh Mohebbi
  • Saman Mohammadi
  • Abbas Pardakhty
  • Sana Eybpoosh
  • Amireh Heshmatkhah
  • Behrooz Vares
  • Simin Saryazdi
  • Ali Reza Fekri
  • Elham Mohebbi
Original Article

Abstract

Zinc sulfate (ZS) has been used for the treatment of acute cutaneous leishmaniasis (CL) in both forms of in vivo and in vitro recently. The aim of the present study was to compare the efficacy of intralesional injection of ZS 2 % solution with intralesional glucantime in the treatment of acute CL. In this double-blind randomized clinical trial, 80 cases with acute old world dry type CL were enrolled in the study. The treatment protocol in the first group consisted of intralesional injection of ZS 2 % vials once a week for 10 weeks or sooner in case of complete resolution of the lesions. In the second group, intralesional glucantime once a week for 10 weeks or sooner in case of complete resolution of the lesions were used. In both groups cryotherapy was performed once every other week for 10 weeks. In ZS versus second group, partial and complete clinical response was observed with fewer injections although this difference was not statistically significant. In addition, we found that the trend of treatment in second group was faster but again it was not significant [partial treatment: hazard ratio (HR) 1.4, 95 % CI 0.7–2.9; complete treatment: HR 1.3, 95 % CI 0.6–2.8]. The results of this study showed that the intralesional injection of ZS 2 % solution was as effective as glucantime on the healing of the acute old world dry type CL.

Keywords

Zinc sulfate Cutaneous leishmaniasis Intralesional Glucantime 

Notes

Acknowledgments

The authors would like to acknowledge the reviewers of our drafts and Afzalipour hospital of University of Medical Sciences, Kerman, Iran.

Conflict of interest

The authors confirmed that they have no financial or personal relationships which may have inappropriately influenced them in writing this paper.

References

  1. Al majalio O, Routh HB (1997) A two year study of liquid nitrogen therapy in cutaneous leishmaniasis. Int J Dermatol 36(6):36–460Google Scholar
  2. Ashford RW (2000) The leishmaniasis as emerging and reemerging zoonoses. Int J Parasitol 30:1269–1281CrossRefPubMedGoogle Scholar
  3. Dogra J, Aneja N, Lal BB, Mishra SN (1990) Cutaneous leishmaniasis in India: clinical experience with itraconazole. Int J Dermatol 29:661–662CrossRefPubMedGoogle Scholar
  4. Esfandiarpour I, Alavi F (1997) Evaluating the efficacy of allopurinol and meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis: a pilot study. Int J Dermatol 36(1):59–60CrossRefGoogle Scholar
  5. Firooz A, Khatami A, Khamesipour A, Nassiri-Kashani M, Behnia F, Nilforoushzadeh M, Pazoki-Toroudi H, Dowlati Y (2004) Intralesional injection of 2 % zinc sulfate solution in the treatment of acute old world cutaneous leishmaniasis: a randomized, double-blinded, controlled clinical trial. J Drug Dermatol 4:73–77Google Scholar
  6. Iraji F, Vali A, Asilian A, Shahtalebi MA, Momeni AZ (2004) Comparison of intralesionally injected zinc sulfate with meglumine antimoniate in the treatment of acute cutaneous leishmaniasis. Dermatology 209(1):46–49CrossRefPubMedGoogle Scholar
  7. Maleki M, Karimi Gh, Tafaghodi M, Raftari S, Nahidi Y (2012) Comparison of intralesional two percent zinc sulfate and glucantime injection in treatment of acute cutaneous leishmaniasis. Indian J Dermatol 57(2):118–122CrossRefPubMedPubMedCentralGoogle Scholar
  8. Minodier P, Parola P (2007) Cutaneous leishmaniasis treatment. Travel Med Infect Dis J 5:150–158CrossRefGoogle Scholar
  9. Najim RA (1998) Zinc sulfate in the treatment of cutaneous leishmaniasis: an in vitro and animal study. Inst Oswaldo Cruz 93:831–833CrossRefGoogle Scholar
  10. Najim RA, Sharquie KE, Al-Zubaidy SA (2006) Possible mechanisms of action of the compounds injected intralesionally in the treatment of cutaneous leishmaniasis, in addition to their direct effects on the parasites. Ann Trop Med Parasitol 100(1):33–38CrossRefPubMedGoogle Scholar
  11. Prasad AS (2009a) Zinc: role in immunity, oxidative stress and chronic inflammation. Curr Opin Clin Nutr Metab Care 12:646–652CrossRefPubMedGoogle Scholar
  12. Prasad AS (2009b) Impact of the discovery of human zinc deficiency on health. J Am Coll Nutr 28:257–265CrossRefPubMedGoogle Scholar
  13. Prata A, Silva-Vergara ML, Costa L, Rocha A, Krolewiecki A, Silva JC, de Paula EV, Pimenta Junior FG, Giraldo LE (2003) Efficacy of azithromycin in the treatment of cutaneous leishmaniasis. Rev Soc Bras Med Trop 36(1):65–69CrossRefPubMedGoogle Scholar
  14. Sharifi I, Fekri AR, Aflatonian MR, Nadim A, Nikian Y, Kamesipour A (1998) Cutaneous leishmaniasis in primary school children in the south-eastern Iranian city of Bam, 1994–1995. Bull World Health Organ 76(3):289–293PubMedPubMedCentralGoogle Scholar
  15. Sharifi F, Sharifi I, Zarean M, Hakimi Parizi M, Aflatoonian M, Harandi MF, Zahmatkesh R, Mashayekhi M, Kermanizadeh A (2012) Spatial distribution and molecular identification of Leishmania species from endemic foci of south-eastern Iran. Iran J Parasitol 7(1):45–52PubMedPubMedCentralGoogle Scholar
  16. Sharquie KL, Najim RA, Farouj IB (1997) Comparative controlled trial of intralesionally administered zinc sulfate, hypertonic sodium chloride and pentavalent antimony compound against acute cutaneous leishmaniasis. Clin Exp Dermatol 22:169–173CrossRefPubMedGoogle Scholar
  17. Sharquie KE, Najim RA, Farjou IB, Al-Timimi DJ (2001) Oral zinc sulfate in the treatment of acute cutaneous leishmaniasis. Clin Exp Dermatol 26:21–26CrossRefPubMedGoogle Scholar
  18. World Health Organization (1984) The leishmaniasis. Report of a WHO expert committee. WHO Tech Rep Ser 701Google Scholar

Copyright information

© Indian Society for Parasitology 2014

Authors and Affiliations

  • Saeedeh Farajzadeh
    • 1
  • Maryam Hakimi Parizi
    • 1
  • Ali Akbar Haghdoost
    • 2
  • Azadeh Mohebbi
    • 3
  • Saman Mohammadi
    • 3
  • Abbas Pardakhty
    • 4
  • Sana Eybpoosh
    • 5
  • Amireh Heshmatkhah
    • 3
  • Behrooz Vares
    • 3
  • Simin Saryazdi
    • 3
  • Ali Reza Fekri
    • 3
  • Elham Mohebbi
    • 6
  1. 1.Leishmaniasis Research CenterKerman University of Medical SciencesKermanIran
  2. 2.Regional Knowledge Hub, and WHO Collaborating Centre for HIV Surveillance, Institute for Futures Studies in HealthKerman University of Medical SciencesKermanIran
  3. 3.Department of DermatologyKerman University of Medical SciencesKermanIran
  4. 4.Pharmaceutics Research CenterKerman University of Medical SciencesKermanIran
  5. 5.Research Center for Social Determinants of Health, Institute for Futures Studies in HealthKerman University of Medical SciencesKermanIran
  6. 6.Research Center for Modeling in Health, Institute of Futures Studies in HealthKerman University of Medical SciencesKermanIran

Personalised recommendations